37 related articles for article (PubMed ID: 17306605)
1. A pilot study to profile salivary angiogenic factors to detect head and neck cancers.
van der Merwe L; Wan Y; Cheong HJ; Perry C; Punyadeera C
BMC Cancer; 2018 Jul; 18(1):734. PubMed ID: 30001714
[TBL] [Abstract][Full Text] [Related]
2. Hepatocyte Growth Factor Overexpression Slows the Progression of 4NQO-Induced Oral Tumorigenesis.
He X; Chen S; Tang Y; Zhao X; Yan L; Wu L; Wu Z; Liu W; Chen X; Wang X
Front Oncol; 2021; 11():756479. PubMed ID: 34970484
[TBL] [Abstract][Full Text] [Related]
3. Tyrosine Kinase c-MET as Therapeutic Target for Radiosensitization of Head and Neck Squamous Cell Carcinomas.
Lüttich L; Besso MJ; Heiden S; Koi L; Baumann M; Krause M; Dubrovska A; Linge A; Kurth I; Peitzsch C
Cancers (Basel); 2021 Apr; 13(8):. PubMed ID: 33919702
[TBL] [Abstract][Full Text] [Related]
4. HGF-Induced PD-L1 Expression in Head and Neck Cancer: Preclinical and Clinical Findings.
Boschert V; Teusch J; Aljasem A; Schmucker P; Klenk N; Straub A; Bittrich M; Seher A; Linz C; Müller-Richter UDA; Hartmann S
Int J Mol Sci; 2020 Nov; 21(22):. PubMed ID: 33233528
[TBL] [Abstract][Full Text] [Related]
5. Failures in preclinical and clinical trials of c-Met inhibitors: evaluation of pathway activity as a promising selection criterion.
Hughes VS; Siemann DW
Oncotarget; 2019 Jan; 10(2):184-197. PubMed ID: 30719213
[TBL] [Abstract][Full Text] [Related]
6. Plasma proteins as prognostic biomarkers in radiotherapy treated head and neck cancer patients.
Brøndum L; Eriksen JG; Singers Sørensen B; Mortensen LS; Toustrup K; Overgaard J; Alsner J
Clin Transl Radiat Oncol; 2017 Feb; 2():46-52. PubMed ID: 29658000
[TBL] [Abstract][Full Text] [Related]
7. Hepatocyte Growth Factor/c-Met Signaling in Head and Neck Cancer and Implications for Treatment.
Rothenberger NJ; Stabile LP
Cancers (Basel); 2017 Apr; 9(4):. PubMed ID: 28441771
[TBL] [Abstract][Full Text] [Related]
8. Cytokines in saliva increase in head and neck cancer patients after treatment.
Russo N; Bellile E; Murdoch-Kinch CA; Liu M; Eisbruch A; Wolf GT; D'Silva NJ
Oral Surg Oral Med Oral Pathol Oral Radiol; 2016 Oct; 122(4):483-490.e1. PubMed ID: 27554375
[TBL] [Abstract][Full Text] [Related]
9. Met degradation by SAIT301, a Met monoclonal antibody, reduces the invasion and migration of nasopharyngeal cancer cells via inhibition of EGR-1 expression.
Lee BS; Kang S; Kim KA; Song YJ; Cheong KH; Cha HY; Kim CH
Cell Death Dis; 2014 Apr; 5(4):e1159. PubMed ID: 24722284
[TBL] [Abstract][Full Text] [Related]
10. MET genetic abnormalities unreliable for patient selection for therapeutic intervention in oropharyngeal squamous cell carcinoma.
Lacroix L; Post SF; Valent A; Melkane AE; Vielh P; Egile C; Castell C; Larois C; Micallef S; Saulnier P; Goulaouic H; Lefebvre AM; Temam S
PLoS One; 2014; 9(1):e84319. PubMed ID: 24465403
[TBL] [Abstract][Full Text] [Related]
11. Recently identified biomarkers that promote lymph node metastasis in head and neck squamous cell carcinoma.
Walk EL; Weed SA
Cancers (Basel); 2011 Feb; 3(1):747-72. PubMed ID: 24212639
[TBL] [Abstract][Full Text] [Related]
12. Receptor-type Protein tyrosine phosphatase β regulates met phosphorylation and function in head and neck squamous cell carcinoma.
Xu Y; Zhou J; Carey TE; McHugh JB; Voorhees JJ; Fisher GJ
Neoplasia; 2012 Nov; 14(11):1015-22. PubMed ID: 23226095
[TBL] [Abstract][Full Text] [Related]
13. Targeting of Both the c-Met and EGFR Pathways Results in Additive Inhibition of Lung Tumorigenesis in Transgenic Mice.
Stabile LP; Rothstein ME; Keohavong P; Lenzner D; Land SR; Gaither-Davis AL; Kim KJ; Kaminski N; Siegfried JM
Cancers (Basel); 2010 Dec; 2(4):2153-70. PubMed ID: 21390244
[TBL] [Abstract][Full Text] [Related]
14. HGF and c-Met participate in paracrine tumorigenic pathways in head and neck squamous cell cancer.
Knowles LM; Stabile LP; Egloff AM; Rothstein ME; Thomas SM; Gubish CT; Lerner EC; Seethala RR; Suzuki S; Quesnelle KM; Morgan S; Ferris RL; Grandis JR; Siegfried JM
Clin Cancer Res; 2009 Jun; 15(11):3740-50. PubMed ID: 19470725
[TBL] [Abstract][Full Text] [Related]
15. Regulatory T cells and their prognostic value for patients with squamous cell carcinoma of the head and neck.
Boucek J; Mrkvan T; Chovanec M; Kuchar M; Betka J; Boucek V; Hladikova M; Betka J; Eckschlager T; Rihova B
J Cell Mol Med; 2010 Jan; 14(1-2):426-33. PubMed ID: 19183242
[TBL] [Abstract][Full Text] [Related]
16. Serum hepatocyte growth factor as a marker of tumor activity in head and neck squamous cell carcinoma.
Kim CH; Lee JS; Kang SO; Bae JH; Hong SP; Kahng H
Oral Oncol; 2007 Nov; 43(10):1021-5. PubMed ID: 17306605
[TBL] [Abstract][Full Text] [Related]
17. Serum concentrations of hepatocyte growth factor in breast cancer patients.
Taniguchi T; Toi M; Inada K; Imazawa T; Yamamoto Y; Tominaga T
Clin Cancer Res; 1995 Sep; 1(9):1031-4. PubMed ID: 9816076
[TBL] [Abstract][Full Text] [Related]
18. The significance of Tenascin-C serum level as tumor marker in squamous cell carcinoma of the head and neck.
Pauli C; Stieber P; Schmitt UM; Andratschke M; Hoffmann K; Wollenberg B
Anticancer Res; 2002; 22(5):3093-7. PubMed ID: 12530049
[TBL] [Abstract][Full Text] [Related]
19. Serum levels of interleukin-6 in patients with primary head and neck squamous cell carcinoma.
Riedel F; Zaiss I; Herzog D; Götte K; Naim R; Hörmann K
Anticancer Res; 2005; 25(4):2761-5. PubMed ID: 16080523
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
